2019年冠状病毒病(COVID-19)
医学
受体
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
爆发
肾
疾病
肺
调节器
2019-20冠状病毒爆发
免疫学
生物信息学
内科学
生物
病理
传染病(医学专业)
遗传学
基因
作者
Shuainan Li,Wenya Ma,Fan Yang,Yan Xu,Binbin Xu,Benzhi Cai
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2021-03-22
卷期号:22 (16): 1832-1843
标识
DOI:10.2174/1389450122666210319110320
摘要
ACE2 has long been known as an injury protective protein, which can protect against a variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases, as a negative regulator of RAAS, ACE2 is an extremely important protective factor that mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2, which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms. Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and cardiovascular diseases/heart injury.
科研通智能强力驱动
Strongly Powered by AbleSci AI